Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Useful for the study of apoptosis, screening inhibitors, and selectivity profiling.

Biochem/physiol Actions

BCL2L1 (B-cell lymphoma 2 like 1) or Bcl-xS functions as a dominant negative regulator of the anti-apoptotic isoform Bcl-xL. Bcl-xL is involved in modulating anti-apoptotic capacity of chemotherapy-resistant tumors. This protein is highly expressed in michigan cancer foundation 7 (MCF7) human breast carcinoma cells, and studies show that overexpression of Bcl-xS in these MCF-7 cells results in heightened sensitivity to chemotherapy-induced apoptosis by agents such as VP-16 or taxol.

General description

BCL2L1 (B-cell lymphoma 2 like 1) gene codes for the anti-apoptotic protein called Bcl-xL (B-cell lymphoma-extra large) and its isoform Bcl-xS. Bcl-xS functions as an antagonist of Bcl-xL. This gene is localized to human chromosome 20q11.21.

Physical form

Formulated in 25 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.05% Tween-20, 30% glycerol and 3 mM DTT.

Preparation Note

Thaw on ice. Upon first thaw, briefly spin tube containing enzyme to recover full content of the tube. Aliquot enzyme into single use aliquots. Store remaining undiluted enzyme in aliquots at -70°C. Note: Enzyme is very sensitive to freeze/thaw cycles.